HUBUNGAN KARAKTERISTIK PASIEN DENGAN TOKSISITAS HEPATOLOGI AKIBAT PENGGUNAAN 6-MERKAPTOPURIN DALAM FASE PEMELIHARAAN PADA PASIEN PEDIATRI KANKER LEUKIMIA LIMFOBLASTIK AKUT DI RS KANKER DHARMAIS JAKARTA

Authors

  • Nazhipah Isnani Politeknik Unggulan Kalimantan
  • Dyah Aryani Perwitasari Universitas Ahmad Dahlan Yogyakarta
  • Rizka Andalusia Rumah Sakit Kanker Dharmais Jakarta
  • Haridini Intan Mahdi Rumah Sakit Kanker Dharmais Jakarta

DOI:

https://doi.org/10.36387/jifi.v3i2.585

Keywords:

6-mercaptopurine, toxicity, hepatology, acute lymphoblastic leukemia

Abstract

Mercaptopurine is a chemotherapy drug that used in the consolidation and maintenance phase in pediatric patients with acute lymphoblastic leukemia ( ALL). Mercaptopurine is supposed to have relationship with the occurrence of toxicity in hepatology. This study was aimed to determine  the patient incidence , severity and management of toxicity and risk factors that affect the occurrence of hepatologic toxicity using of  6 - MP in the maintenance phase in pediatric patients with acute lymphoblastic leukemia in Dharmais Cancer Hospital Jakarta.

This research was carried out by cross-sectional observational design with data was taken retrospectively and prospectively during the period from March to April 2014. The study subjects were patient who have been getting treatment of maintenace phase in Dharmais Cancer Hospital Jakarta from 2013 until March-April 2014. The Subjects who met the inclusion criteria were 23 patients of ALL received 6 - MP in the maintenance phase. Data was collected by looking at the medical records for getting of the patient's identity and data hepatology. The result showed that there was a correlation between patient characterision on hepatology toxicity, on SGOT age and weight with SGPT both of them has significant value, it was 0,036 (P<0,05)

References

Kementrian Kesehatan, 2011, Pedoman Penuaan Dini Kanker Pada Anak, Kesehatan Ridirektorat Jenderal Pp & Pldirektorat Pengendalian Penyakit Tidak Menular, Jakarta.

Suryaningrat, F,R., Primadi, A., Chairulalfatah, A., 2019, Perbandingan Efektifitas Antara Monoterapi Empiris Seftazidime dan Sefepim pada Anak Leukemia Limfoblastik Akut dengan Demam Neutropenia, Sari Pediatri, 21 (2) :81-88.

Teheteru, E, S., 2011, Gambaran Tingkat Remisi pada LeukemiaLimfoblastik Akut setelah Fase Induksi diBangsal Kanker Anak RS Kanker “Dharmaisâ€Â, Indonesian Journal of Cancer, 5 (4) :159-162.

Brandalise, R.S., Pinheiro, V.S., Aguiar, S.S., et al, 2010, Benefits of the Intermittent Use of 6-Mercaptopurine and Methotrexate in Maintenance Treatment for Low-Risk Acute Lymphoblastic Leukemia in Children: Randomized Trial From the Brazilian Childhood Cooperative Groupâ€â€Protocol ALL-99, J of Clin Onc, 28 (11) : 1911-1918.

Vagace, J.M and Gervasini. G., 2011, Acute Leukemia - The Scientist's Perspective and Challenge, editored in Mariastefania Antica, 391-414, InTech Europe.

Beaumais, T. A. D., Fakhoury, M., Medard, Y., et al, 2010, Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukimia Maintenance Therapy, Br J of Clin Pharmacol, 71 (4) : 575-584.

Pinontoan, E., Mantik, M and Rampengan, N., 2012, Pengaruh Kemoterapi terhadap Profil Hematologi pada Penderita Leukimia Limfoblastik Akut, Ilmu Kesehatan Anak FK Unsrat, Manado.

Supriyadi, E., Widjajanto, P.H., Purwanto, I., et al, 2011, Immunophenotypic Patterns of Childhood Acute Leukemias in Indonesia, Asian Pac J Can Prevent, 12 : 3381-3387.

National Cancer Institute, 2014, Childhood Acute Lymphoblastic Leukemia Treatment, http://www.cancer.gov/cancertopics/pdq/treatment/Child ALL, diakses tanggal 3 Mei 2014.

Rini, T. A., Aisyi, M., Sari, Y., and Edi, S.T., 2009, Karakteristik Leukemia Limfoblastik Akut pada Anak di Rumah Sakit Kanker Dharmais 2000-2008, Ind J Cancer, 4 (4) : 137-140.

Maria, E, S., Ulrikka, N., Sussane, R., Ditte, S., Jacob, N., Kim, V., Finn, W., Joh, K., Arja, H-S., Kjeld, S., 2017, Hepatotoxicity During Maintenance Therapy and Prognosis in Children With Acute Lymphoblastic Leukemia, Journal of Pediatric Hematology/Oncology, 39 (3) : 161-166.

Toksvang, L, N., Schmidt, M,S., Arup, S., Larsen, R, H., Frandsen, T, L., Schmiegelow, K., Rank, C, U., 2019, Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia : Asystematicreview, https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0212157&type=printable, accesed on 27th November, 2020.

Published

2020-12-28

How to Cite

1.
HUBUNGAN KARAKTERISTIK PASIEN DENGAN TOKSISITAS HEPATOLOGI AKIBAT PENGGUNAAN 6-MERKAPTOPURIN DALAM FASE PEMELIHARAAN PADA PASIEN PEDIATRI KANKER LEUKIMIA LIMFOBLASTIK AKUT DI RS KANKER DHARMAIS JAKARTA. JIFI [Internet]. 2020 Dec. 28 [cited 2026 Apr. 21];3(2):361-8. Available from: https://e-jurnal.stikes-isfi.ac.id/index.php/JIFI/article/view/585